Joe McCann
Long/short equity, growth, medium-term horizon

Cologuard Will Dominate Its Addressable Market

The last few weeks have seen a heated debate on Seeking Alpha and Twitter regarding the prospects of Exact Sciences' (NASDAQ:EXAS) Cologuard, once the seemingly inevitable FDA approval comes June 6th. Looking at the Bull vs. Bear argument in the market, I found myself initially inclined to be skeptical of the prospects for a test that was cutting the market by a 3rd (once every 3 years vs. annual) and 20 times the cost of the current standard of care. My experiences with the BRCA test and Sequenom's (NASDAQ:SQNM) Maternit21 launch left me generally bearish on a diagnostic launch.

However, a long time ago, I learned that one can't rely on which argument made by other...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
  • Access Top Ideas, chosen by Seeking Alpha’s editors
  • Filter long and short ideas by market cap and sector
  • Get Coverage of over 5,000 stocks, many of which have little or no coverage elsewhere
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO." Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else." Patrick Rice, Mainstay Capital Management
100% Satisfaction Guaranteed
Money back guarantee. Seeking Alpha PRO members receive a no-questions-asked refund for membership on months paid and not used. Details